全文获取类型
收费全文 | 277693篇 |
免费 | 40861篇 |
国内免费 | 2758篇 |
专业分类
耳鼻咽喉 | 6792篇 |
儿科学 | 8757篇 |
妇产科学 | 4656篇 |
基础医学 | 20235篇 |
口腔科学 | 4142篇 |
临床医学 | 39530篇 |
内科学 | 73396篇 |
皮肤病学 | 9458篇 |
神经病学 | 27129篇 |
特种医学 | 10571篇 |
外国民族医学 | 5篇 |
外科学 | 59250篇 |
综合类 | 2454篇 |
现状与发展 | 73篇 |
一般理论 | 184篇 |
预防医学 | 18618篇 |
眼科学 | 6292篇 |
药学 | 10070篇 |
2篇 | |
中国医学 | 183篇 |
肿瘤学 | 19515篇 |
出版年
2023年 | 5169篇 |
2022年 | 1864篇 |
2021年 | 5116篇 |
2020年 | 7146篇 |
2019年 | 4193篇 |
2018年 | 9645篇 |
2017年 | 8991篇 |
2016年 | 10206篇 |
2015年 | 10699篇 |
2014年 | 18725篇 |
2013年 | 20779篇 |
2012年 | 13515篇 |
2011年 | 14072篇 |
2010年 | 15002篇 |
2009年 | 18494篇 |
2008年 | 13994篇 |
2007年 | 12806篇 |
2006年 | 15004篇 |
2005年 | 12684篇 |
2004年 | 11459篇 |
2003年 | 10275篇 |
2002年 | 9873篇 |
2001年 | 5242篇 |
2000年 | 4270篇 |
1999年 | 4669篇 |
1998年 | 5321篇 |
1997年 | 4842篇 |
1996年 | 4506篇 |
1995年 | 4317篇 |
1994年 | 2903篇 |
1993年 | 2546篇 |
1992年 | 2303篇 |
1991年 | 2290篇 |
1990年 | 1897篇 |
1989年 | 1982篇 |
1988年 | 1733篇 |
1987年 | 1535篇 |
1986年 | 1547篇 |
1985年 | 1490篇 |
1984年 | 1489篇 |
1983年 | 1425篇 |
1982年 | 1724篇 |
1981年 | 1488篇 |
1980年 | 1333篇 |
1979年 | 839篇 |
1978年 | 940篇 |
1977年 | 971篇 |
1976年 | 733篇 |
1975年 | 715篇 |
1974年 | 639篇 |
排序方式: 共有10000条查询结果,搜索用时 765 毫秒
71.
72.
Alan. B. Franklin Sarah N. Bevins Jeremy W. Ellis Ryan S. Miller Susan A. Shriner J. Jeffrey Root Daniel P. Walsh Thomas J. Deliberto 《Transboundary and Emerging Diseases》2019,66(2):705-714
Using data on waterfowl band recoveries, we identified spatially explicit hotspots of concentrated waterfowl movement to predict occurrence and spatial spread of a novel influenza A virus (clade 2.3.4.4) introduced from Asia by waterfowl from an initial outbreak in North America in November 2014. In response to the outbreak, the hotspots of waterfowl movement were used to help guide sampling for clade 2.3.4.4 viruses in waterfowl as an early warning for the US poultry industry during the outbreak . After surveillance sampling of waterfowl, we tested whether there was greater detection of clade 2.3.4.4 viruses inside hotspots. We found that hotspots defined using kernel density estimates of waterfowl band recoveries worked well in predicting areas with higher prevalence of the viruses in waterfowl. This approach exemplifies the value of ecological knowledge in predicting risk to agricultural security. 相似文献
73.
Srdan Verstovsek MD PhD Jean-Jacques Kiladjian MD PhD Alessandro M. Vannucchi MD Ruben A. Mesa MD FACP Peg Squier MD PhD J. E. Hamer-Maansson MSPH Claire Harrison MD 《Cancer》2023,129(11):1681-1690
Background
In a pooled analysis of the phase 3 Controlled Myelofibrosis Study With Oral JAK Inhibitor Treatment I (COMFORT-I) and COMFORT-II clinical trials, adult patients with intermediate-2 or high-risk myelofibrosis who received oral ruxolitinib at randomization or after crossover from placebo or best available therapy (BAT) had improved overall survival (OS).Methods
This post hoc analysis of pooled COMFORT data examined relevant disease outcomes based on the disease duration (≤12 or >12 months from diagnosis) before ruxolitinib initiation.Results
The analysis included 525 patients (ruxolitinib: ≤12 months, n = 84; >12 months, n = 216; placebo/BAT: ≤12 months, n = 66; >12 months, n = 159); the median age was 65.0–70.0 years. Fewer thrombocytopenia and anemia events were observed among patients who initiated ruxolitinib treatment earlier. At Weeks 24 and 48, the spleen volume response (SVR) was higher for patients who initiated ruxolitinib earlier (47.6% vs. 32.9% at Week 24, p = .0610; 44.0% vs. 26.9% at Week 48, p = .0149). In a multivariable analysis of factors associated with spleen volume reduction, a logistic regression model that controlled for confounding factors found that a significantly greater binary reduction was observed among patients with shorter versus longer disease duration (p = .022). At Week 240, OS was significantly improved among patients who initiated ruxolitinib earlier (63% [95% CI, 51%‒73%] vs. 57% [95% CI, 49%‒64%]; hazard ratio, 1.53; 95% CI, 1.01‒2.31; p = .0430). Regardless of disease duration, a longer OS was observed for patients who received ruxolitinib versus those who received placebo/BAT.Conclusions
These findings suggest that earlier ruxolitinib initiation for adult patients with intermediate-2 and high-risk myelofibrosis may improve clinical outcomes, including fewer cytopenia events, durable SVR, and prolonged OS.Plain Language Summary
- Patients with myelofibrosis, a bone marrow cancer, often do not live as long as the general population. These patients may also have an enlarged spleen and difficult symptoms such as fatigue.
- Two large clinical trials showed that patients treated with the drug ruxolitinib lived longer and had improved symptoms compared to those treated with placebo or other standard treatments.
- Here it was examined whether starting treatment with ruxolitinib earlier (i.e., within a year of diagnosis) provided benefits versus delaying treatment.
- Patients who received ruxolitinib within a year of diagnosis lived longer and experienced fewer disease symptoms than those whose treatment was delayed.
74.
75.
76.
Nicola Flaum Emma J. Crosbie Richard J. Edmondson Miriam J. Smith Dafydd G. Evans 《Clinical genetics》2020,97(1):54-63
Ovarian cancer is the fourth most common cause of cancer-related death in women in the developed world, and one of the most heritable cancers. One of the most significant risk factors for epithelial ovarian cancer (EOC) is a family history of breast and/or ovarian cancer. Combined risk factors can be used in models to stratify risk of EOC, and aid in decisions regarding risk-reduction strategies. Germline pathogenic variants in EOC susceptibility genes including those involved in homologous recombination and mismatch repair pathways are present in approximately 22% to 25% of EOC. These genes are associated with an estimated lifetime risk of EOC of 13% to 60% for BRCA1 variants and 10% to 25% for BRCA2 variants, with lower risks associated with remaining genes. Genome-wide association studies have identified single nucleotide polymorphisms (SNPs) thought to explain an additional 6.4% of the familial risk of ovarian cancer, with 34 susceptibility loci identified to date. However, an unknown proportion of the genetic component of EOC risk remains unexplained. This review comprises an overview of individual genes and SNPs suspected to contribute to risk of EOC, and discusses use of a polygenic risk score to predict individual cancer risk more accurately. 相似文献
77.
78.
79.
80.
Jennifer Novak Yujie Cui Paul Frankel Mina S. Sedrak Scott Glaser Richard Li Sabin Motwani Brian Kavanagh Arya Amini 《Practical radiation oncology》2021,11(3):e263-e266
PurposeTwitter is an increasingly popular social media platform within the health care community. The objective of this analysis is to characterize the profile of radiation oncology–related tweets and Twitter users over the past 6 years.Methods and MaterialsUsing the web-based social media analytics platform Symplur Signals, we filtered tweets containing at least 1 of the following hashtags or key words: #radonc, #radiationoncology, "rad onc," or "radiation oncology." We evaluated radiation oncology–related Twitter activity between October 2014 and March 2020 for tweet frequency, tweet content, and individuals or groups posting tweets. We identified the most influential Twitter users contributing to radiation oncology–related tweets.ResultsFrom 2014 to 2020, the quarterly volume of radiation oncology–related tweets increased from 5027 to 29,763. Physicians contributed the largest growth in tweet volume. Academic radiation oncologists comprise 60% of the most influential Twitter accounts responsible for radiation oncology–related content. The number of radiation-oncology resident physicians on Twitter increased from 25 to 328 over the past 6 years, and 20% of radiation-oncology residency programs have a Twitter account. Seventy-one percent of radiation oncology–related tweets generated direct communication via mentions, and 59% of tweets contain links to external sources, including scientific articles.ConclusionsThe number of physicians contributing radiation oncology–related Twitter content has increased significantly in recent years. Academic radiation oncologists are the primary influencers of radiation oncology–related Twitter activity. Twitter is used by radiation oncologists to both professionally network and discuss findings related to the field. There remains the opportunity for radiation oncologists to broaden their audience on Twitter to encompass a more diverse community, including patients. 相似文献